FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092741397> ?p ?o ?g. }

• W2092741397 abstract "You have accessJournal of UrologyProstate Cancer: Basic Research1 Apr 20111624 LOW TEMPERATURE-SENSITIVE LIPOSOME ENCAPSULATED DOCETAXEL AND DOXORUBICIN IN A XENOGRAFT MURINE MODEL OF PROSTATE CANCER Saurin Chokshi, Compton Benjamin, Ashish Ranjan, Paul Chung, Ayele Negussie, Ardeshir Rastinehad, Katherine Klos, Matthew Dreher, W. Marston Linehan, Bradford Wood, and Peter Pinto Saurin ChokshiSaurin Chokshi Bethesda, MD More articles by this author , Compton BenjaminCompton Benjamin Bethesda, MD More articles by this author , Ashish RanjanAshish Ranjan Bethesda, MD More articles by this author , Paul ChungPaul Chung Bethesda, MD More articles by this author , Ayele NegussieAyele Negussie Bethesda, MD More articles by this author , Ardeshir RastinehadArdeshir Rastinehad Bethesda, MD More articles by this author , Katherine KlosKatherine Klos Bethesda, MD More articles by this author , Matthew DreherMatthew Dreher Bethesda, MD More articles by this author , W. Marston LinehanW. Marston Linehan Bethesda, MD More articles by this author , Bradford WoodBradford Wood Bethesda, MD More articles by this author , and Peter PintoPeter Pinto Bethesda, MD More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1732AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Low-temperature sensitive liposomes (LTSLs) release their encapsulated drug into targeted tissue when activated by a source of hyperthermia. The efficacy of an LTSL formulation of docetaxel (DOC) or doxorubicin (DOX) was compared against prostate cancer in a xenograft mouse model. METHODS Under an approved IACUC protocol, Luciferase transfected human prostate PC-3M-luciferase cells were inoculated (3×106 cells) subcutaneously in the right hind leg of 8 wk old female athymic nude mice. When tumors reached a volume of 200–300 mm3, mice were randomized to receive one intravenous injection of saline, Stealth liposomal DOX (5 mg/kg), LTSL DOX (5 mg/kg), or LTSL DOC (15 mg/kg), with or without hyperthermia treatment (LTSL DOX and LTSL DOC were supplied by Celsion Corp., Columbia, MD). Mice undergoing hyperthermia treatment were anesthetized and stabilized in a holder that allowed for only the leg with tumor to be heated to 41–42C that triggered LTSL drug release. Mice were monitored daily for tumor volume and body weight. Study end-points included growth of tumor to 5x the initial treatment volume or monitoring of survival for 60 days. RESULTS The LTSL DOC delayed tumor growth longer (20 days) than DOX (7 days) or LTSL DOX (9 days) with hyperthermia (P<0.05). Mice treated with LTSL DOC and hyperthermia survived longest (60 days) compared to all other mice (range 6–8 days, P<0.05). LTSL in the setting of hyperthermia demonstrated complete regression of tumor in 57% of mice. CONCLUSIONS LTSL DOC with hyperthermia delayed tumor growth more than all other treatments. Survival studies suggest LTSL DOC is a more effective temperature sensitive delivery system against PC-3M prostate tumors. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e651 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Saurin Chokshi Bethesda, MD More articles by this author Compton Benjamin Bethesda, MD More articles by this author Ashish Ranjan Bethesda, MD More articles by this author Paul Chung Bethesda, MD More articles by this author Ayele Negussie Bethesda, MD More articles by this author Ardeshir Rastinehad Bethesda, MD More articles by this author Katherine Klos Bethesda, MD More articles by this author Matthew Dreher Bethesda, MD More articles by this author W. Marston Linehan Bethesda, MD More articles by this author Bradford Wood Bethesda, MD More articles by this author Peter Pinto Bethesda, MD More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2092741397 created "2016-06-24" @default.
• W2092741397 creator A5006366911 @default.
• W2092741397 creator A5014134590 @default.
• W2092741397 creator A5019280982 @default.
• W2092741397 creator A5021288206 @default.
• W2092741397 creator A5026470145 @default.
• W2092741397 creator A5038850729 @default.
• W2092741397 creator A5054252052 @default.
• W2092741397 creator A5055473847 @default.
• W2092741397 creator A5073816304 @default.
• W2092741397 creator A5079851122 @default.
• W2092741397 creator A5082375022 @default.
• W2092741397 date "2011-04-01" @default.
• W2092741397 modified "2023-09-25" @default.
• W2092741397 title "1624 LOW TEMPERATURE-SENSITIVE LIPOSOME ENCAPSULATED DOCETAXEL AND DOXORUBICIN IN A XENOGRAFT MURINE MODEL OF PROSTATE CANCER" @default.
• W2092741397 doi "https://doi.org/10.1016/j.juro.2011.02.1732" @default.
• W2092741397 hasPublicationYear "2011" @default.
• W2092741397 type Work @default.
• W2092741397 sameAs 2092741397 @default.
• W2092741397 citedByCount "2" @default.
• W2092741397 countsByYear W20927413972015 @default.
• W2092741397 countsByYear W20927413972017 @default.
• W2092741397 crossrefType "journal-article" @default.
• W2092741397 hasAuthorship W2092741397A5006366911 @default.
• W2092741397 hasAuthorship W2092741397A5014134590 @default.
• W2092741397 hasAuthorship W2092741397A5019280982 @default.
• W2092741397 hasAuthorship W2092741397A5021288206 @default.
• W2092741397 hasAuthorship W2092741397A5026470145 @default.
• W2092741397 hasAuthorship W2092741397A5038850729 @default.
• W2092741397 hasAuthorship W2092741397A5054252052 @default.
• W2092741397 hasAuthorship W2092741397A5055473847 @default.
• W2092741397 hasAuthorship W2092741397A5073816304 @default.
• W2092741397 hasAuthorship W2092741397A5079851122 @default.
• W2092741397 hasAuthorship W2092741397A5082375022 @default.
• W2092741397 hasConcept C121608353 @default.
• W2092741397 hasConcept C126322002 @default.
• W2092741397 hasConcept C143998085 @default.
• W2092741397 hasConcept C2776235491 @default.
• W2092741397 hasConcept C2776694085 @default.
• W2092741397 hasConcept C2780192828 @default.
• W2092741397 hasConcept C2781190966 @default.
• W2092741397 hasConcept C2781303535 @default.
• W2092741397 hasConcept C29456083 @default.
• W2092741397 hasConcept C502942594 @default.
• W2092741397 hasConcept C71924100 @default.
• W2092741397 hasConceptScore W2092741397C121608353 @default.
• W2092741397 hasConceptScore W2092741397C126322002 @default.
• W2092741397 hasConceptScore W2092741397C143998085 @default.
• W2092741397 hasConceptScore W2092741397C2776235491 @default.
• W2092741397 hasConceptScore W2092741397C2776694085 @default.
• W2092741397 hasConceptScore W2092741397C2780192828 @default.
• W2092741397 hasConceptScore W2092741397C2781190966 @default.
• W2092741397 hasConceptScore W2092741397C2781303535 @default.
• W2092741397 hasConceptScore W2092741397C29456083 @default.
• W2092741397 hasConceptScore W2092741397C502942594 @default.
• W2092741397 hasConceptScore W2092741397C71924100 @default.
• W2092741397 hasIssue "4S" @default.
• W2092741397 hasLocation W20927413971 @default.
• W2092741397 hasOpenAccess W2092741397 @default.
• W2092741397 hasPrimaryLocation W20927413971 @default.
• W2092741397 hasRelatedWork W1898921923 @default.
• W2092741397 hasRelatedWork W2010765098 @default.
• W2092741397 hasRelatedWork W2060708716 @default.
• W2092741397 hasRelatedWork W2094570582 @default.
• W2092741397 hasRelatedWork W2588988563 @default.
• W2092741397 hasRelatedWork W2735900144 @default.
• W2092741397 hasRelatedWork W2770702948 @default.
• W2092741397 hasRelatedWork W3023947295 @default.
• W2092741397 hasRelatedWork W3155233782 @default.
• W2092741397 hasRelatedWork W4226303148 @default.
• W2092741397 hasVolume "185" @default.
• W2092741397 isParatext "false" @default.
• W2092741397 isRetracted "false" @default.
• W2092741397 magId "2092741397" @default.
• W2092741397 workType "article" @default.